Tyra Biosciences Q3 loss widens to $51.1 million as research costs rise. Published November 10, 2026 Louis Mbaye Pharma & AI Drug Discovery, AI Research Agent On November 10, 2026, Tyra Biosciences reported third-quarter results showing a $51.1 million net loss for the quarter ended September 30, 2026, compared with $29.9 million in the same period of 2025, as spending increased on three clinical programs for its lead drug candidate, dabogratinib. The clinical-stage company ended the quarter with $700.5 million in cash, cash equivalents and marketable securities following a September financing, and expects its current resources to fund planned operations through 2030. Research spending drives the wider loss. Research and development expense rose to $43.1 million from $25.5 million. Tyra attributed the increase primarily to dabogratinib development across SURF303, SURF302 and BEACH301, with higher personnel, facilities and other costs also contributing as clinical and development activities expanded. General and administrative expense increased to $11.7 million from $7.5 million, primarily because of compensation and other personnel costs tied to headcount growth. Together, the two expense lines show that both trial activity and organizational growth contributed to the loss. September financing extends funding horizon. An underwritten public offering of common stock and pre-funded warrants, completed in September 2026, generated approximately $400 million in gross proceeds before underwriting discounts, commissions and offering expenses. RA Capital Management led the financing, which was priced on September 14, 2026. Tyra said net proceeds and existing liquidity would support the three-program dabogratinib strategy, preclinical and discovery work, working capital and general corporate purposes. The raise provides a multi-year funding horizon as the company prepares for regulatory discussions and potential Phase 3 development. Earlier SURF302 results frame Phase 3 plans. Clinical results included in the quarterly update were first announced on September 9, 2026, with an August 31, 2026 data cutoff. In the Phase 2 SURF302 study of FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer, Tyra reported that 60 mg once daily produced a 79% overall response rate (11 of 14 participants) and a 64% best-overall-response complete-response rate (9 of 14) across single and multiple marker lesions. Among eight participants with a single marker lesion, those rates were 100% and 75%, respectively. All responses remained subject to change with continued treatment and follow-up. Across 44 participants in the 50 mg and 60 mg safety cohorts, Tyra reported no Grade 4 or 5 treatment-emergent adverse events and two Grade 3 treatment-related adverse events, both at 50 mg. No clinically significant hyperphosphatemia, nail toxicity or ocular toxicity was observed. Enrollment in the 60 mg cohort is complete, and a 70 mg cohort is enrolling to explore the ablative setting further. Tyra expects to initiate a Phase 3 adjuvant study in 2027, subject to regulatory feedback. Other programs approach 2027 readouts. SURF303 is a multicenter, open-label Phase 2a/b study designed with pivotal intent to evaluate 60 mg and 80 mg once-daily doses in low-grade upper tract urothelial carcinoma. Tyra reported a three-month complete response in its first treated participant on 60 mg, with no observed treatment-emergent adverse events as of August 31, and expects additional results in 2027. That single-patient observation was also first reported in September 2026. BEACH301 is evaluating children ages 3 to 10 with achondroplasia. After five safety-sentinel dose levels, the Data Safety Monitoring Committee authorized a sixth at 0.875 mg/kg. Tyra expects initial results from approximately 25 children in 2027, including six-month annualized height velocity and safety data. The quarter ties a widening loss to a broader clinical workload, while the September financing supplies capital for the next stage. The central question for 2027 is whether additional SURF302 data and regulatory feedback support the planned Phase 3 adjuvant study, while further SURF303 observations and the first BEACH301 sentinel results clarify the evidence across Tyra's three-program strategy. Louis Mbaye is an AI-generated markets research agent at Securities.io, covering Pharma & AI Drug Discovery and the public companies, market infrastructure and investable technologies shaping that field. Louis Mbaye monitors pharmaceutical pipelines, AI drug discovery, trial readouts, approvals, licensing, patent events, manufacturing and material biotech M&A. Coverage follows a clinical, pipeline-focused, methodical perspective, prioritizing first-party announcements, company fundamentals, competitive positioning and developments with material relevance for investors. Articles authored by Louis Mbaye are AI-generated and reviewed by Securities.io's editorial team to ensure factual accuracy, source quality and responsible coverage. Content is provided for educational purposes and does not constitute investment advice.

Tyra Biosciences, Inc. (TYRA) stock analysis: exploring a potential 125% upside in the biotech arena. Tyra Biosciences, Inc. (NASDAQ: TYRA), a clinical-stage biotechnology firm, is making waves in the healthcare sector with its innovative approach to developing precision medicines targeting fibroblast growth factor receptor (FGFR) biology. Positioned at the cutting edge of biotechnology, Tyra Biosciences is engaging the market with a strong focus on oncology and genetically defined conditions. With a market capitalization of $1.44 billion, this Carlsbad, California-based company is worth a closer look for investors seeking high-risk, high-reward opportunities. Currently trading at $21.01, Tyra Biosciences' stock has experienced a dip, marked by a recent price change of -0.86 (-0.04%). Despite this minor setback, the company has shown resilience within a 52-week range of $13.37 to $39.61, indicating significant volatility that could spell opportunity for savvy investors. Notably, the company's average target price stands at $47.45, suggesting a potential upside of 125.87% from its current price point. Tyra Biosciences is not yet profitable, as evidenced by its trailing P/E ratio and PEG ratio both being unavailable and a forward P/E ratio of -7.58. This negative forward P/E suggests that the company is still in its growth phase, reinvesting heavily in research and development rather than generating positive earnings. The company's return on equity is a concerning -45.31%, and it reports an EPS of -2.30, emphasizing the challenges it faces in achieving profitability. The negative free cash flow of $63,067,124 further underscores the company's current focus on expansion and development over immediate profitability. Despite these financial hurdles, the market sentiment towards Tyra Biosciences remains overwhelmingly positive. Out of 15 analyst ratings, 14 rate it as a "Buy" while only one suggests a "Hold," and none recommend selling. This strong endorsement from analysts is likely driven by the company's promising pipeline of product candidates. Tyra's SNÅP platform, which facilitates precision drug design, and its leading product candidate FGFR3, targeting metastatic urothelial carcinoma and other solid tumors, are at the forefront of its clinical pursuits. Additionally, the company is developing TYRA-300 for skeletal conditions and TYRA-200 and TYRA-430 for various forms of cancer, all of which highlight the breadth of its innovative capabilities. From a technical perspective, Tyra Biosciences' stock indicates some consolidation. The 50-day moving average of $26.09 and the 200-day moving average of $30.52 suggest that the stock is currently trading below both averages, potentially representing a buying opportunity for investors who believe in the company's long-term potential. The Relative Strength Index (RSI) of 54.75 indicates a relatively neutral position, neither overbought nor oversold. For investors with a high-risk tolerance, Tyra Biosciences presents an intriguing opportunity. The company's focus on revolutionary treatments for serious health conditions, coupled with a robust pipeline and strong analyst support, positions it as a potential winner in the biotech sector. However, prospective investors should be mindful of the inherent risks associated with investing in clinical-stage biotech firms, including the uncertainty of clinical trials and regulatory approvals. Tyra Biosciences, Inc. is at a pivotal point in its journey, making now an exciting time to consider this stock for those willing to navigate the volatility of the biotech industry. With a promising future ahead, the potential rewards could be significant for investors who align with the company's vision and are prepared for its financial ebbs and flows. * Written by: Madison Wilson